Blog
EQS-News: Francotyp-Postalia Holding AG: Acquisition of treasury shares – 26th interim report
EQS-News: Francotyp-Postalia Holding AG: Acquisition of treasury shares – 26th interim report
EQS-News: Electronic Arts (EA) Co-Founder Jeff Burton Joins P2Earn as New Advisory Board Chairman
EQS-News: Electronic Arts (EA) Co-Founder Jeff Burton Joins P2Earn as New Advisory Board Chairman
EQS-News: Enapter AG: Final figures for fiscal year 2022 published
EQS-News: Enapter AG: Final figures for fiscal year 2022 published
Dalata Hotel Group PLC: Total Voting Rights
Dalata Hotel Group PLC: Total Voting Rights
EQS-News: K.B. Recycling Industries Ltd. Announces Name Change
EQS-News: K.B. Recycling Industries Ltd. Announces Name Change
EQS-News: q.beyond subsidiary logineer becomes one of the largest CargoWise service partners
EQS-News: q.beyond subsidiary logineer becomes one of the largest CargoWise service partners
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Fuller, Smith & Turner PLC: Total Voting Rights
Fuller, Smith & Turner PLC: Total Voting Rights
SThree: TVR-Total Voting Rights
SThree: TVR-Total Voting Rights
Nordea Bank Abp: Transaction in Own Shares
Nordea Bank Abp: Transaction in Own Shares
Rights and Issues Investment Trust PLC: TVR-Total Voting Rights
Rights and Issues Investment Trust PLC: TVR-Total Voting Rights
EQS-News: ENCAVIS AG improves carbon footprint and documents emission levels
EQS-News: ENCAVIS AG improves carbon footprint and documents emission levels
EQS-News: NorCom Information Technology GmbH & Co. KGaA: NorCom impresses with DaSense Community Open Source at the Fujitsu Annual Conference on Digital Management
EQS-News: NorCom Information Technology GmbH & Co. KGaA: NorCom impresses with DaSense Community Open Source at the Fujitsu Annual Conference on Digital Management
EQS-News: Rubean AG successfully completes capital measure to finance growth successfully
EQS-News: Rubean AG successfully completes capital measure to finance growth successfully
Thalassa Holdings Ltd: Temporary Suspension
Thalassa Holdings Ltd: Temporary Suspension
EQS-Adhoc: Correction of a release from 02/05/2023, 08:10 CET/CEST - PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
EQS-Adhoc: Correction of a release from 02/05/2023, 08:10 CET/CEST - PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
Alina Holdings PLC: Temporary Suspension
Alina Holdings PLC: Temporary Suspension
EQS-News: PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
EQS-News: PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
EQS-Adhoc: PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
EQS-Adhoc: PATRIZIA SE: PATRIZIA accelerates its global growth ambitions with appointment of Asoka Wöhrmann as CEO Designate and Slava Shafir as COO
EQS-News: American West continues its fantastic success story at Storm copper project
EQS-News: American West continues its fantastic success story at Storm copper project
EQS-News: Fintech aifinyo AG after record year on track for profitable growth in Q1 2023
EQS-News: Fintech aifinyo AG after record year on track for profitable growth in Q1 2023
Cairn Homes Plc Transaction in Own Shares
Cairn Homes Plc Transaction in Own Shares
Biophytis strengthens its management team
Biophytis strengthens its management team
EQS-News: Defence Therapeutics Inc.: DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING
EQS-News: Defence Therapeutics Inc.: DEFENCE’S SUCCESFULL ACCUTOXTM PRE-CLINICAL EFFICACY STUDY COMPLETE READY FOR PHASE I IND FILING


